Sugi Predict

Sugi Predict / Compounds / SCHEMBL4716342

SCHEMBL4716342

SCHEMBL4716342

CN1CCC2(CC1)CCN(C(=O)c1cccc(N3Cc4cccc(Cl)c4C3=O)c1)CC2

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BDKRB1 P46663 1/20 0.77
▸ MAPK1 P28482 1/20 0.54
▸ USP2 O75604 3/20 0.43
▸ CYP1A2 P05177 3/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HTR2A P28223 2/20 0.43
▸ HTR2C P28335 2/20 0.43
▸ HTR2B P41595 2/20 0.43
▸ GABRD O14764 1/20 0.43
▸ GABRA1 P14867 1/20 0.43
▸ GABRB1 P18505 1/20 0.43
▸ GABRA5 P31644 1/20 0.43
▸ GABRA3 P34903 1/20 0.43
▸ GABRA2 P47869 1/20 0.43
▸ GABRB2 P47870 1/20 0.43
▸ GABRA4 P48169 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712523 0.91 BDKRB1 (0.72) BDKRB1MAPK1USP2CYP1A2CYP3A4
SCHEMBL4717762 0.90 BDKRB1 (0.74) BDKRB1MAPK1USP2CYP1A2CYP3A4
SCHEMBL4714147 0.88 BDKRB1 (0.69) BDKRB1MAPK1USP2CYP1A2CYP3A4
SCHEMBL1712902 0.87 BDKRB1 (1.00) BDKRB1MAPK1USP2CYP1A2CYP3A4
SCHEMBL5630639 0.86 BDKRB1 (0.61) BDKRB1HTR2AHTR2CHTR2BEGFR
SCHEMBL4760693 0.84 BDKRB1 (0.66) BDKRB1MAPK1USP2HTR2AHTR2C
SCHEMBL4714598 0.83 BDKRB1 (0.58) BDKRB1MEN1KMT2AHTR2AHTR2C
SCHEMBL4716396 0.83 BDKRB1 (0.61) BDKRB1MEN1KMT2AHTR2AHTR2C
SCHEMBL13985122 0.83 BDKRB1 (0.66) BDKRB1MAPK1USP2CYP1A2CYP3A4
SCHEMBL4716862 0.82 BDKRB1 (0.64) BDKRB1MAPK1USP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 — — US claimed
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 — — EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 — — US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 — — US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 — — US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 BDKRB1 1/4885MAPK1 712/4885USP2 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.